Patents by Inventor Joshua BREUNIG

Joshua BREUNIG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230084201
    Abstract: Described herein are donor vectors and systems for use in in vivo dual recombinase-mediated cassette exchange. Also described are animal models for consistent, rigorous, and facile investigation of transgene expression. Further described are methods of screening for therapeutic drugs using these animal models, and methods of treatment.
    Type: Application
    Filed: September 8, 2022
    Publication date: March 16, 2023
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Joshua BREUNIG, Moise DANIELPOUR, Gi Bum KIM
  • Patent number: 11466290
    Abstract: Described herein are donor vectors and systems for use in in vivo dual recombinase-mediated cassette exchange. Also described are animal models for consistent, rigorous, and facile investigation of transgene expression. Further described are methods of screening for therapeutic drugs using these animal models, and methods of treatment.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: October 11, 2022
    Assignee: Cedars-Sinai Medical Center
    Inventors: Joshua Breunig, Moise Danielpour, Gi Bum Kim
  • Publication number: 20220304286
    Abstract: Described herein are donor vectors and systems for use in dual recombinase-mediated cassette exchange. Also described herein are animal models and human cells for consistent, rigorous, and facile investigation of transgene expression. Further described herein are methods of screening for therapeutic drugs using these animal models, and methods of treatment.
    Type: Application
    Filed: June 16, 2020
    Publication date: September 29, 2022
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Joshua Breunig, Moise Danielpour, Gi Bum Kim, Alberto Ayala-Sarmiento, Amy Yang
  • Publication number: 20210024955
    Abstract: Delivery of glial cell line-derived neurotrophic factor (GDNF) has provided benefits to Parkinsonian patients and is currently being tested in a Phase 1/2a clinical trial for ALS patients. However, chronic trophic factor delivery prohibits dose adjustment or shut off in the event of side effects. To address this, the Inventors engineered a stably integrating, third-generation doxycycline-regulated vector, allowing inducible and reversible expression of a therapeutic molecule Human iPSC-derived neural progenitors were stably transfected with the vector, expanded and transplanted into the adult mouse brain. The Inventors observed that the addition and withdrawal of doxycycline led to GDNF expression that could be induced and reversed multiple times, demonstrating that doxycycline can penetrate the graft and regulate transgene expression in vivo.
    Type: Application
    Filed: March 15, 2019
    Publication date: January 28, 2021
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Clive Svendsen, Joshua Breunig, Aslam Akhtar
  • Patent number: 10786537
    Abstract: The present invention provide for methods of inducing an oncolytic effect on tumor cells using Zika virus. The invention also provides for inducing an oncolytic effect on brain tumors and treating brain tumors, and in particular, glioblastomas and neuroblastoma. The treatment involves the administration of Zika virus, which has an oncolytic effect on the tumor cells.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: September 29, 2020
    Assignee: Cedars-Sinai Medical Center
    Inventors: Vaithilingaraja Arumugaswami, Joshua Breunig
  • Patent number: 10612022
    Abstract: Described herein are composition and methods related to targeting the Nf1-Ras-Ets axis, that when perturbed, is identified as playing a role in initiation and maintenance in glioma. A postnatal, mosaic, autochthonous, glioma model that captures the first hours and days of gliomagenesis in more resolution than conventional genetically engineered mouse models of cancer demonstrates that disruption of the Nf1-Ras pathway in the ventricular zone at multiple signaling nodes uniformly results in rapid neural stem cell depletion, progenitor hyperproliferation, and gliogenic lineage restriction. By abolishing Ets subfamily activity, which is upregulated downstream of Ras, there is block of glioma initiation, thereby providing new therapeutic avenues for targeting glioma.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: April 7, 2020
    Assignee: Cedars-Sinai Medical Center
    Inventors: Joshua Breunig, Moise Danielpour
  • Publication number: 20190390222
    Abstract: Described herein are donor vectors and systems for use in in vivo dual recombinase-mediated cassette exchange. Also described are animal models for consistent, rigorous, and facile investigation of transgene expression.
    Type: Application
    Filed: December 30, 2016
    Publication date: December 26, 2019
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Joshua BREUNIG, Moise DANIELPOUR, Gi Bum KIM
  • Publication number: 20190192593
    Abstract: The present invention provide for methods of inducing an oncolytic effect on tumor cells using Zika virus. The invention also provides for inducing an oncolytic effect on brain tumors and treating brain tumors, and in particular, glioblastomas and neuroblastoma. The treatment involves the administration of Zika virus, which has an oncolytic effect on the tumor cells.
    Type: Application
    Filed: August 17, 2017
    Publication date: June 27, 2019
    Applicant: Cedars-Sinai Medical Center
    Inventors: Vaithilingaraja ARUMUGASWAMI, Joshua BREUNIG
  • Publication number: 20180291375
    Abstract: Described herein are composition and methods related to targeting the Nf1-Ras-Ets axis, that when perturbed, is identified as playing a role in initiation and maintenance in glioma. A postnatal, mosaic, autochthonous, glioma model that captures the first hours and days of gliomagenesis in more resolution than conventional genetically engineered mouse models of cancer demonstrates that disruption of the Nf1-Ras pathway in the ventricular zone at multiple signaling nodes uniformly results in rapid neural stem cell depletion, progenitor hyperproliferation, and gliogenic lineage restriction. By abolishing Ets subfamily activity, which is upregulated downstream of Ras, there is block of glioma initiation, thereby providing new therapeutic avenues for targeting glioma.
    Type: Application
    Filed: May 20, 2016
    Publication date: October 11, 2018
    Applicant: Cedars-Sinai Medical Center
    Inventors: Joshua BREUNIG, Moise DANIELPOUR